Posted 3/13/2024, 9:47:13 AM
AI-Designed Drug Enters Historic Clinical Trials for Lung Disease
- An experimental drug designed with AI has entered clinical trials in China and the US to treat lung disease IPF, a first for an AI-generated drug
- The drug was developed by AI firm Insilico Medicine in just 18 months from target discovery to clinical trials
- Insilico trained AI models on biology data to identify the antifibrotic target protein TNIK and design an optimal inhibitor compound
- Simultaneous phase 2a trials with 60 patients each in China and the US will test the safety, tolerability, pharmacokinetics and efficacy
- While AI can accelerate early drug discovery, clinical trials still require extensive time for regulatory approval, patient recruitment and data analysis